![]() |
市场调查报告书
商品编码
1561540
2024-2032 年医疗迴旋加速器市场报告(按类型(环形迴旋加速器、方位角变化场迴旋加速器)、产品类型、最终用户和地区)Medical Cyclotron Market Report by Type (Ring Cyclotron, Azimuthally Varying Field Cyclotron), Product Type, End User, and Region 2024-2032 |
2023年,全球医疗迴旋加速器市场规模达到2.3IMARC Group美元。癌症盛行率的增加、放射性药物的进步、对正子断层扫描(PET) 扫描的需求不断增长、技术创新、医疗保健基础设施的扩大、研究活动的增加以及促进核医学和诊断成像的政府支持措施是增强市场的一些关键因素生长。
癌症和慢性病盛行率上升
医疗迴旋加速器市场研究报告显示,推动市场的主要趋势之一是全球癌症和其他慢性疾病发生率的增加。癌症仍然是全球主要死亡原因之一,需要先进的诊断工具来进行早期发现和治疗。 2022 年,有 970 万人死亡,5,350 万人被诊断出罹患癌症。医用迴旋加速器在生产 PET 扫描中使用的放射性同位素方面发挥着至关重要的作用,这种同位素对于早期检测各种类型的癌症非常有效。此外,心血管疾病 (CVD) 和神经系统疾病等慢性疾病的盛行率不断上升,增加了对精确诊断影像技术的需求。由于医疗保健系统强调早期诊断和有效的治疗计划,对可靠和高品质放射性同位素的需求正在推动医疗迴旋加速器市场的成长。
放射性药物的进展
放射性药物在核子医学的诊断和治疗方面发挥着至关重要的作用。最近的进步导致了更精确和更有针对性的放射性药物的开发,提高了诊断成像和治疗的准确性和有效性。放射性药物的这项创新扩大了其应用范围,能够诊断和治疗肿瘤学以外的更广泛的疾病,包括心臟病学和神经病学。此外,人工智慧和机器学习 (ML) 在放射性药物研究中的整合刺激了新化合物的开发,改善了患者的治疗效果。这些进步需要生产新型放射性同位素,进而推动医用迴旋加速器市场规模的发展。
扩大医疗基础设施和诊断影像投资
医疗保健基础设施的扩张极大地促进了市场的成长。公共和私人组织都在建造配备尖端诊断成像设备的尖端医疗设施方面进行了大量投资。医院和诊断诊所越来越多地设立 PET 和 PET-CT 中心,这有助于市场扩张。此外,政府的有利倡议和促进核医学和诊断成像的资金进一步支持了市场成长。例如,各国正在实施政策,以改善先进诊断工具的取得并确保基本放射性药物的供应。这对医疗迴旋加速器的市场前景产生了积极影响,因为它们对于生产这些尖端成像方法所需的放射性同位素至关重要。
IMARC Group提供了每个细分市场的主要趋势的分析,以及 2024-2032 年全球、区域和国家层面的预测。我们的报告根据类型、产品类型和最终用户对市场进行了分类。
环形迴旋加速器占大部分市场份额
该报告根据类型提供了详细的市场细分和分析。这包括环形迴旋加速器和方位变场 (AVF) 迴旋加速器。根据该报告,环形迴旋加速器代表了最大的部分。
根据医疗迴旋加速器行业统计数据,环形迴旋加速器因其在生产 PET 等先进诊断成像技术所必需的高能量放射性同位素方面的卓越能力而占据市场主导地位。他们的设计允许连续有效地加速粒子,从而产生更高纯度和一致性的放射性同位素产量。环形迴旋加速器由于其效率而非常适合医疗设施中的大规模生产,从而保证了基本放射性药物的持续供应。此外,他们的先进技术支援更广泛的同位素,满足肿瘤学以外的各种医疗应用,例如心臟病学和神经学。高产能、可靠性和多功能性的结合使环形迴旋加速器成为医疗迴旋加速器市场的首选。
迴旋加速器16-18 MeV占业界最大份额
报告还根据产品类型对市场进行了详细的细分和分析。这包括迴旋加速器10-12 MeV、迴旋加速器16-18 MeV、迴旋加速器19-24 MeV和迴旋加速器24 MeV以上。报告称,16-18 MeV迴旋加速器占据了最大的市场份额。
对16-18 MeV能阶迴旋加速器的需求主要是由其生产能力和运作效率之间的最佳平衡所驱动的。 Fluorine-18 是 PET 成像所必需的,它是这些迴旋加速器可以产生的众多放射性同位素之一。 16-18 MeV 能量范围可以高效生产高纯度同位素,产量足以满足大型医院和商业无线电药房的需求。此外,这些迴旋加速器具有成本效益,可为医疗设施提供良好的投资回报。 16-18 MeV 迴旋加速器的多功能性与支援多种诊断和治疗应用的能力相结合,成为业界的首选。
医院代表领先的细分市场
该报告提供了基于最终用户的详细市场细分和分析。这包括医院、诊断中心、研究和学术机构等。报告称,医院占最大部分。
医疗迴旋加速器市场洞察表明,医院作为最大的最终用户,在提供先进的诊断和治疗服务方面发挥关键作用。医院的医用迴旋加速器生产用于 PET 和 SPECT 成像的重要放射性同位素,这对于诊断和监测各种疾病(包括癌症、心血管疾病和神经系统疾病)至关重要。将迴旋加速器整合到医院环境中可确保及时可靠地供应这些放射性药物,从而改善病患照护和治疗效果。此外,内部生产放射性同位素的成长趋势使医院能够减少对外部供应商的依赖,降低营运成本,并提高核医部门的效率。
亚太地区引领市场,占据最大的医疗迴旋加速器市场份额
该报告还对所有主要区域市场进行了全面分析,其中包括北美(美国和加拿大);欧洲(德国、法国、英国、义大利、西班牙、俄罗斯等);亚太地区(中国、日本、印度、韩国、澳洲、印尼等);拉丁美洲(巴西、墨西哥等);以及中东和非洲。报告称,亚太地区是医疗迴旋加速器最大的区域市场。
医疗迴旋加速器市场分析显示,由于医疗保健基础设施的强劲扩张,亚太地区成为领先地区,特别是在中国、日本和印度等国家,这增加了对先进诊断和治疗技术的需求。政府投资的增加和优惠政策支持医疗机构采用医用迴旋加速器。此外,该地区癌症和其他慢性病盛行率的上升加大了对先进成像和治疗解决方案的需求,进一步推动市场成长。领先的迴旋加速器製造商的存在以及核子医学领域不断增长的研发 (R&D) 活动也有助于该地区的主导地位。
(请注意,这只是关键参与者的部分列表,报告中提供了完整列表。)
The global medical cyclotron market size reached US$ 230.0 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 453.4 Million by 2032, exhibiting a growth rate (CAGR) of 7.6% during 2024-2032. The increasing cancer prevalence, advancements in radiopharmaceuticals, rising demand for positron emission tomography (PET) scans, technological innovations, expanding healthcare infrastructure, growing research activities, and supportive government initiatives promoting nuclear medicine and diagnostic imaging are some of the key factors strengthening the market growth.
Rising prevalence of cancer and chronic diseases
Medical cyclotron market research report shows that one of the primary trends driving the market is the increasing incidence of cancer and other chronic diseases worldwide. Cancer remains one of the leading causes of death globally, necessitating advanced diagnostic tools for early detection and treatment. In 2022, there were 9.7 million deaths and 53.5 million living with a cancer diagnosis. Medical cyclotrons play a crucial role in producing radioisotopes used in PET scans, which are highly effective in detecting various types of cancers at an early stage. Additionally, the escalating prevelance of chronic diseases such as cardiovascular disorders (CVD) and neurological conditions has increased the demand for precise diagnostic imaging techniques. As healthcare systems emphasize early diagnosis and effective treatment plans, the need for reliable and high-quality radioisotopes is bolstering the medical cyclotron market growth.
Advancements in radiopharmaceuticals
Radiopharmaceuticals play a crucial role in nuclear medicine for both diagnostic and therapeutic purposes. Recent advancements have led to the development of more precise and targeted radiopharmaceuticals, enhancing the accuracy and effectiveness of diagnostic imaging and treatments. This innovation in radiopharmaceuticals has expanded their application scope, enabling the diagnosis and treatment of a broader range of diseases beyond oncology, including cardiology and neurology. Moreover, the integration of AI and machine learning (ML) in radiopharmaceutical research has spurred the development of new compounds, improving patient outcomes. These advancements necessitate the production of novel radioisotopes, thereby providing an impetus to the medical cyclotron market size.
Expanding healthcare infrastructure and investments in diagnostic imaging
The expansion of healthcare infrastructure significantly contributes to the market growth. Both public and private organizations are making significant investments in the construction of cutting-edge medical facilities outfitted with cutting-edge diagnostic imaging equipment. The increasing establishment of PET and PET-CT centers in hospitals and diagnostic clinics is aiding in market expansion. Moreover, favorable government initiatives and funding to promote nuclear medicine and diagnostic imaging are further supporting the market growth. For instance, various countries are implementing policies to improve access to advanced diagnostic tools and ensure the availability of essential radiopharmaceuticals. This is positively impacting the medical cyclotron market outlook because they are essential for producing the radioisotopes needed for these cutting-edge imaging methods.
IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on type, product type, and end user.
Ring cyclotron accounts for the majority of the market share
The report has provided a detailed breakup and analysis of the market based on the type. This includes ring cyclotron and azimuthally varying field (AVF) cyclotron. According to the report, ring cyclotron represented the largest segment.
As per the medical cyclotron industry statistics, ring cyclotrons dominate the market due to their superior capabilities in producing high-energy radioisotopes essential for advanced diagnostic imaging techniques like PET. Their design allows for continuous and efficient acceleration of particles, resulting in higher yields of radioisotopes with greater purity and consistency. Ring cyclotrons are well-suited for large-scale production in medical facilities owing to their efficiency, which guarantees a consistent supply of essential radiopharmaceuticals. Additionally, their advanced technology supports a wider range of isotopes, catering to diverse medical applications beyond oncology, such as cardiology and neurology. The combination of high production capacity, reliability, and versatility positions ring cyclotrons as the preferred choice in the medical cyclotron market.
Cyclotron 16-18 MeV holds the largest share of the industry
A detailed breakup and analysis of the market based on the product type have also been provided in the report. This includes cyclotron 10-12 MeV, cyclotron 16-18 MeV, cyclotron 19-24 MeV, and cyclotron 24 MeV and above. According to the report, cyclotron 16-18 MeV accounted for the largest market share.
The demand for cyclotrons with 16-18 MeV energy levels is mainly driven by their optimal balance between production capacity and operational efficiency. Fluorine-18, which is essential for PET imaging, is among the many radioisotopes that can be produced by these cyclotrons. The 16-18 MeV energy range allows for efficient production of high-purity isotopes with sufficient yield to meet the demands of both large hospitals and commercial radio pharmacies. Additionally, these cyclotrons are cost-effective, offering a favorable return on investment for medical facilities. Their versatility, combined with the ability to support diverse diagnostic and therapeutic applications, makes 16-18 MeV cyclotrons the preferred choice in the industry.
Hospitals represent the leading market segment
The report has provided a detailed breakup and analysis of the market based on the end user. This includes hospitals, diagnostic centers, research and academic institutes, and others. According to the report, hospitals represented the largest segment.
Medical cyclotron market insights exhibit hospitals as the biggest end users with their critical role in providing advanced diagnostic and therapeutic services. Medical cyclotrons in hospitals produce essential radioisotopes used in PET and SPECT imaging, which are pivotal for diagnosing and monitoring various diseases, including cancer, CVDs, and neurological disorders. The integration of cyclotrons within hospital settings ensures a timely and reliable supply of these radiopharmaceuticals, enhancing patient care and treatment outcomes. Furthermore, the growing trend of in-house production of radioisotopes allows hospitals to reduce dependence on external suppliers, lower operational costs, and improve the efficiency of their nuclear medicine departments.
Asia Pacific leads the market, accounting for the largest medical cyclotron market share
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, Asia Pacific represents the largest regional market for medical cyclotron.
Medical cyclotron market analysis revealed Asia Pacific as the leading region due to robust healthcare infrastructure expansion, particularly in countries like China, Japan, and India, which boosts the demand for advanced diagnostic and therapeutic technologies. Increasing government investments and favorable policies support the adoption of medical cyclotrons in healthcare facilities. Additionally, the rising prevalence of cancer and other chronic diseases in the region amplifies the need for advanced imaging and treatment solutions, further driving market growth. The presence of leading cyclotron manufacturers and growing research and development (R&D) activities in nuclear medicine also contribute to the region's dominance.
(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)